[{"id":"3394a8c8-2d3a-47af-8e85-851b55f69cb0","acronym":"CerebralEDV","url":"https://clinicaltrials.gov/study/NCT02766699","created_at":"2021-01-18T13:34:05.356Z","updated_at":"2024-07-02T16:36:56.125Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)","source_id_and_acronym":"NCT02766699 - CerebralEDV","lead_sponsor":"Engeneic Pty Limited","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • doxorubicin hydrochloride • doxorubicin encapsulated nanocells (EGFREDVDox)"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 10/25/2016","start_date":" 10/25/2016","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 06/01/2020","study_completion_date":" 06/01/2020","last_update_posted":"2019-08-29"}]